Target Zero is a new initiative that aims to improve the time to access for patients in Canada for new drugs that are proven to be effective.
The ambitious goal of Target Zero is to achieve zero days between Health Canada’s regulatory approval of a drug and CADTH’s reimbursement recommendation to participating public drug plans.
CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in health technology assessments (HTAs).
We are testing a new approach that brings the societal perspective to our economic evaluations of certain new drugs.
Current Consultation Status: Open
Consultation Period Extended: March 28 to May 3, 2024
CADTH is updating the procedures for provisional funding algorithms as part of our commitment to examine new ways of working and our ongoing efforts to improve the drug reimbursement pathway.
Qualified rare disease registry owners can submit funding proposals to enhance the infrastructure, data quality, and utility of rare disease registries.
CADTH is launching an open call for funding to support efforts to improve the quality and usability of real-world data from rare disease registries.
Submission deadline: Friday, May 10, 2024
Nominations are now being accepted for 4 prestigious awards for outstanding achievement in the field of health technology assessment (HTA) in Canada.
The Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment recognizes individuals whose outstanding achievements have significantly advanced the field of HTA in Canada.